Società CSL Limited

CSL

AU000000CSL8

Prodotti farmaceutici

Consensus Analisti

Attività

Vendite per attività

Vendite per regione

Dirigenti

Amministratori

Classe di azioni

Azionisti

Partecipazioni

Coordinate società

Società del gruppo

Settore

Vendite per attività

Vendite per regione

Rating per CSL Limited

Revisioni EPS

Utili trimestrali - Indice di sorpresa

Settore Biofarmaci

Mercato chiuso - Australian S.E. Altri mercati azionari 08:10:45 26/04/2024			Variaz. 5gg	Var. 1 gen.
273,3 ^AUD	-1,85%		+1,41%	-4,66%

26/04	Le azioni australiane crollano con il calo dei minatori e dei titoli energetici; il Gruppo BHP crolla	RE
24/04	CSL Vifor e Travere Therapeutics annunciano che la Commissione Europea approva FILSPARI® (sparsentan) per il trattamento della Nefropatia IgA	CI

CSL Limited è una società di biotecnologie con sede in Australia. Le aree di interesse dell'azienda comprendono le malattie rare e gravi, i vaccini antinfluenzali, la carenza di ferro e la nefrologia. I segmenti dell'azienda comprendono CSL Behring, CSL Seqirus e CSL Vifor. Il segmento CSL Behring produce, commercializza e distribuisce prodotti al plasma, terapie geniche e ricombinanti. Il segmento CSL Seqirus produce, commercializza e distribuisce prevalentemente prodotti legati all'influenza e fornisce servizi pandemici ai governi. Il segmento CSL Vifor produce, commercializza e distribuisce prodotti nelle aree terapeutiche della carenza di ferro e della nefrologia. CSL Plasma gestisce reti di raccolta del plasma, con oltre 325 centri di raccolta del plasma negli Stati Uniti, in Europa e in Cina. L'Azienda opera in Australia, Stati Uniti, Germania, Regno Unito, Svizzera e Cina. I suoi prodotti includono Respreeza, Zemaira, HAEGARDA, KCENTRA, Epatite B, Evogam e altri.

Numero di dipendenti: 32 065

AUD in Milioni	2022	Peso	2023	Peso	Delta
CSL Behring 69,8 %	11 857	81,4 %	13 811	69,8 %	+16,48%
CSL Seqirus 15,3 %	2 708	18,6 %	3 019	15,3 %	+11,52%
CSL Vifor 14,9 %	-	-	2 957	14,9 %	-

AUD in Milioni	2022	Peso	2023	Peso	Delta
United States 49,3 %	7 065	48,5 %	9 757	49,3 %	+38,10%
Rest of World 21,4 %	2 776	19,1 %	4 236	21,4 %	+52,59%
Australia 7,9 %	1 409	9,7 %	1 554	7,9 %	+10,23%
Germany 6,5 %	1 077	7,4 %	1 292	6,5 %	+19,93%
China 5,9 %	1 027	7,0 %	1 158	5,9 %	+12,79%
United Kingdom 5,4 %	822	5,6 %	1 066	5,4 %	+29,68%
Switzerland 3,7 %	388	2,7 %	725	3,7 %	+86,90%

Dirigenti	Titolo	Età	Da
Paul McKenzie CEO	Chief Executive Officer	58	01/06/19
Joy Carolyn Linton DFI	Director of Finance/CFO	59	01/10/20
Mark Hill CTO	Chief Tech/Sci/R&D Officer	62	01/10/20
William Mezzanotte CTO	Chief Tech/Sci/R&D Officer	66	01/10/18
Andrew Nash CTO	Chief Tech/Sci/R&D Officer	-	01/11/06
Andrew Cuthbertson BRD	Director/Board Member	70	01/03/97
Mark Dehring IRC	Investor Relations Contact	-	-
Kate Priestman PRN	Corporate Officer/Principal	-	11/09/23
Ken Lim PRN	Corporate Officer/Principal	50	01/01/13
Bill Campbell PRN	Corporate Officer/Principal	64	01/01/14

Amministratori	Titolo	Età	Da
Carolyn Hewson BRD	Director/Board Member	69	09/12/19
Brian McNamee PSD	President	68	01/07/90
Alison Watkins BRD	Director/Board Member	61	19/08/21
Andrew Cuthbertson BRD	Director/Board Member	70	01/03/97
Megan Clark BRD	Director/Board Member	66	16/02/16
Marie McDonald BRD	Director/Board Member	68	14/08/13
Sam Lewis BRD	Director/Board Member	-	01/01
Duncan Maskell BRD	Director/Board Member	63	18/08/21
Paul McKenzie CEO	Chief Executive Officer	58	01/06/19

	Voto	Quantità	Flottante	Autocontrollo	Flottante totale
Azione A	1	483 093 257	480 846 726 ( 99,53 %)	0	99,53 %

Nome	Azioni	%	Valorizzazione
State Street Global Advisors Trust Co. 1,107 %	5 349 487	1,107 %	1 005 M $
Colonial First State Investments Ltd. 0,9797 %	4 734 581	0,9797 %	889 M $
Commonwealth Superannuation Corp. (Investment Management) 0,6784 %	3 278 217	0,6784 %	616 M $
Netwealth Investments Ltd. 0,5316 %	2 568 812	0,5316 %	483 M $
Australian Foundation Investment Co. Ltd. (Invt Mgmt) 0,5030 %	2 431 000	0,5030 %	457 M $
BetaShares Capital Ltd. 0,3329 %	1 608 787	0,3329 %	302 M $
AMP Capital Investors Ltd. 0,2738 %	1 322 973	0,2738 %	249 M $
Argo Investments Ltd. (Investment Management) 0,2594 %	1 253 509	0,2594 %	235 M $
State Street Global Advisors Ltd. 0,2178 %	1 052 335	0,2178 %	198 M $
Australian Eagle Asset Management Pty Ltd. 0,2019 %	975 763	0,2019 %	183 M $

Nome	Azioni	%	Valorizzazione
SILVERCREST ASSET MANAGEMENT GROUP INC. 0,006264 %	60 545	0,006264 %	6 M $
Boston Common Asset Management LLC 0,004533 %	43 811	0,004533 %	4 M $
Domini Impact Investments LLC 0,003321 %	32 100	0,003321 %	3 M $
Yousif Capital Management LLC 0,001734 %	16 760	0,001734 %	2 M $
RhumbLine Advisers LP 0,001472 %	14 227	0,001472 %	1 M $
Budapest Fund Management Co. Ltd. 0,000507 %	4 901	0,000507 %	460 302 $
SVB Wealth LLC 0,000405 %	3 919	0,000405 %	368 072 $
GAMMA Investing LLC 0,000171 %	1 652	0,000171 %	155 156 $
Ametos Invest GmbH 0,000124 %	1 200	0,000124 %	112 704 $
PNC Investments LLC 0,000017 %	161	0,000017 %	15 121 $

Nome	Azioni	%	Valorizzazione
CARA THERAPEUTICS, INC. 13.53%	7 396 770	13.53%	6 731 061 $

CSL Ltd.

655 Elizabeth Street

3000, Melbourne

+61 3 9389 1911

http://www.csl.com.au

Nome	Categoria e settore
CSL Behring LLC CSL Behring LLC BiotechnologyHealth Technology CSL Behring LLC researches, develops, manufactures, and markets biotherapies that are used to treat serious and rare conditions. It offers protein-based therapies in the areas of Bleeding Disorders, Fluid Replacement, Hereditary Angioedema, Immunoglobulin, Pulmonary, and Wound Healing Therapies. The company was founded in 2004 and is headquartered in King of Prussia, PA.	Biotechnology
CSL Behring AG CSL Behring AG BiotechnologyHealth Technology Part of CSL Ltd., CSL Behring AG is a Swiss company that develops biological products. The private company is based in Bern, Switzerland.	Biotechnology
CSL Behring UK Ltd. CSL Behring UK Ltd. Pharmaceuticals: MajorHealth Technology Part of CSL Ltd., CSL Behring UK Ltd. is a private company that manufactures and supplies plasma therapies. The company is based in Haywards Heath, UK. The British company was founded in 1916 by Emil von Behring.	Pharmaceuticals: Major
CSL Behring GmbH CSL Behring GmbH Pharmaceuticals: MajorHealth Technology Part of CSL Ltd., CSL Behring GmbH is a German company that actively collaborates to develop special programs and activities for patients with rare diseases. The private company is based in Marburg, Germany. The CEOs of the company are Lutz Guenter Bonacker, Michael Schröder, Craig Shelanskey.	Pharmaceuticals: Major
CSL Behring Beteiligungs- und Verwaltungs GmbH & Co. KG CSL Behring Beteiligungs- und Verwaltungs GmbH & Co. KG Pharmaceuticals: MajorHealth Technology Part of CSL Ltd., CSL Behring Beteiligungs- und Verwaltungs GmbH & Co. KG is a German pharmaceutical company that manufactures pharmaceutical products. The private company is based in Marburg, Germany. The company was founded in 2004. The CEO is Craig Shelanskey.	Pharmaceuticals: Major
CSL Plasma GmbH CSL Plasma GmbH Medical/Nursing ServicesHealth Services CSL Plasma GmbH provides plasma collection and donation services. It specializes in the collection, testing, and management of plasma taken from blood donors. It focuses on the use of plasma as a key ingredient for products crucial to treating patients suffering from hemophilia, shock or trauma, immune deficiencies, and other blood disorders. It operates through its testing laboratories, collection facilities, and logistics centers. The company is headquartered in Marburg, Germany.	Medical/Nursing Services
CSL Finance GmbH CSL Finance GmbH Financial ConglomeratesFinance Part of CSL Ltd., CSL Finance GmbH is a German company that provides investment services. The company is based in Marburg, Germany. The CEOs are Antje Michel, Dieter Engstfeld, John Andrew Goodman Levy. The private company was founded in 2014.	Financial Conglomerates
CSL Behring Recombinant Facility AG CSL Behring Recombinant Facility AG BiotechnologyHealth Technology Part of CSL Ltd., CSL Behring Recombinant Facility AG is a Swiss biotherapeutics company that develops and delivers innovative therapies to improve patients' lives. The private company is based in Bern, Switzerland and has a manufacturing site there. The company's portfolio includes a wide range of recombinant and plasma-derived products.	Biotechnology
CSL Behring Lengnau AG

Rating Trading

Rating Investimento

ESG Refinitiv

A-

Altri rating

Vendita

Buy

Raccomandazione media

Accumulate

Numero di analisti

Ultimo prezzo di chiusura

178,2 USD

Prezzo obiettivo medio

199,4 USD

Differenza / Target Medio

+11,88%

Consenso

Revisioni delle Stime

Calendario della società

Biotecnologia/Farmaceutici

Biotecnologia/Farmaceutici

Prodotti farmaceutici

Biofarmaci

	Variaz. 1 gen.	Capi.
CSL LIMITED	-4,66%	86,13 Mrd
SAMSUNG BIOLOGICS CO.,LTD.	+1,32%	39,82 Mrd
BIOGEN INC.	-19,27%	30,42 Mrd
UCB	+57,86%	25,23 Mrd
BIOMARIN PHARMACEUTICAL INC.	-16,09%	15,36 Mrd
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9,14%	11,95 Mrd
INCYTE CORPORATION	-17,69%	11,6 Mrd
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43,00%	11,51 Mrd
SWEDISH ORPHAN BIOVITRUM AB	+5,24%	8,71 Mrd
INNOVENT BIOLOGICS, INC.	-8,42%	8,12 Mrd

Biofarmaci